Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring.

Therapeutic drug monitoring (TDM) of aminoglycosides has been a topic during the last thirty years. There is a tendency that - because of the once-daily regimen - TDM is considered not necessary anymore. Although once daily dosing has the potential for decreased toxicity, long-term usage can cause severe nephro- and ototoxicity. Furthermore, inadequate plasma concentrations can lead to treatment failure. This work is devoted to the development and application of the first mathematical model of aminoglycosides, which simulates in relation to the pharmacokinetics both their effects on bacteria as well as their nephrotoxicity and cochleotoxicity. Our software system is suitable for TDM. Based on theoretical considerations, a multi-compartment mathematical model in a numerical program in Matlab is derived that incorporates the antimicrobial effects of aminoglycosides, the saturable and active uptake into kidney cells, the reversible nephrotoxicity and the irreversible cochleotoxicity. Using fictitious person data, and an assumed pharmacokinetic and dynamic parameter set obtained from the literature, we simulated the drug concentrations, antibacterial effects, and toxicity over time in virtual patients to illustrate the benefits of optimized, efficacious dosage regimens that minimize (acceptable) nephro- and auditory ototoxicity. Our model confirms that extended-interval dosing seems the most appropriate to achieve this goal. By this manner, the present mathematical model contributes to an increase in our knowledge of how to obtain an optimized dosing strategy for individual patients. With the developed program, we are able to demonstrate that optimal aminoglycoside dosing still needs a sophisticated system of TDM.

[1]  M. Falagas,et al.  Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. , 2005, The Lancet. Infectious diseases.

[2]  D. Nicolau,et al.  Extended interval aminoglycoside dosing: from concept to clinic. , 2002, International journal of antimicrobial agents.

[3]  Cees Neef,et al.  Analogy between temperature-dependent and concentration-dependent bacterial killing , 2002, Comput. Biol. Medicine.

[4]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  L. Rybak,et al.  Drug ototoxicity. , 1986, Annual review of pharmacology and toxicology.

[6]  R. Jelliffe,et al.  Aminoglycoside Dosages and Nephrotoxicity , 2003, Clinical pharmacokinetics.

[7]  Y. Almog,et al.  Pharmacokinetic dosing of aminoglycosides: a controlled trial. , 2003, The American journal of medicine.

[8]  D. Leehey,et al.  Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. , 1993, Journal of the American Society of Nephrology : JASN.

[9]  T. Murakami,et al.  Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[10]  M. D. de Broe,et al.  In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. , 1986, The Journal of pharmacology and experimental therapeutics.

[11]  A. Zavascki Continuous intravenous administration of antibiotics. , 2006, The Lancet. Infectious diseases.

[12]  R. Jelliffe,et al.  Aminoglycoside Nephrotoxicity: Modeling, Simulation, and Control , 2003, Antimicrobial Agents and Chemotherapy.

[13]  N. Benowitz,et al.  Once-daily dosing of aminoglycosides: how much monitoring is truly required? , 2003, The American journal of medicine.

[14]  C H Nightingale,et al.  A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. , 1986, Journal of pharmaceutical sciences.

[15]  C H Nightingale,et al.  Experience with a once-daily aminoglycoside program administered to 2,184 adult patients , 1995, Antimicrobial agents and chemotherapy.

[16]  X. Barbaut,et al.  Comparisons between Antimicrobial Pharmacodynamic Indices and Bacterial Killing as Described by Using the Zhi Model , 1998, Antimicrobial Agents and Chemotherapy.

[17]  G. Drusano,et al.  Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity , 1999, Antimicrobial Agents and Chemotherapy.

[18]  H. Neu,et al.  The Aminoglycosides: Microbiology, Clinical Use, and Toxicology , 1982 .

[19]  F. O. Black,et al.  Permanent Gentamicin Vestibulotoxicity , 2004, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[20]  G. Mulder,et al.  Isolated proximal tubular cells from rat kidney as an in vitro model for studies on nephrotoxicity. I. An improved method for preparation of proximal tubular cells and their functional characterization by alpha-methylglucose uptake. , 1989, Toxicology and applied pharmacology.

[21]  M. D. de Broe,et al.  Renal cortical uptake kinetics of gentamicin in rats with impaired renal function. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  R. Jelliffe,et al.  Estimation of creatinine clearance from changing serum-creatinine levels. , 1971, Lancet.

[23]  M. D. de Broe,et al.  The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  A. Nafziger,et al.  Application of Bayes Theorem to Aminoglycoside‐Associated Nephrotoxicity: Comparison of Extended‐Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple‐Daily Dosing , 2004, Journal of clinical pharmacology.

[25]  A. Vinks,et al.  Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. , 1997, The Journal of antimicrobial chemotherapy.

[26]  P. Tulkens,et al.  Aminoglycosides: Nephrotoxicity , 1999, Antimicrobial Agents and Chemotherapy.

[27]  J. Schacht,et al.  Aspirin attenuates gentamicin ototoxicity: From the laboratory to the clinic , 2007, Hearing Research.

[28]  A. Nunnery Antimicrobial therapy of gram-negative infections. , 1971, Postgraduate medicine.

[29]  Wilhelm Huisinga,et al.  Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  E. Kuijper,et al.  Once versus thrice daily gentamicin in patients with serious infections , 1993, The Lancet.

[31]  A. Vinks The application of population pharmacokinetic modeling to individualized antibiotic therapy. , 2002, International journal of antimicrobial agents.

[32]  M. D. de Broe,et al.  Aminoglycoside nephrotoxicity: mechanism and prevention. , 1989, Advances in experimental medicine and biology.

[33]  Frieder Keller,et al.  Mechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[34]  F. Hoek,et al.  Circadian rhythm of glomerular filtration rate in normal individuals. , 1989, Clinical science.